Anthem Biosciences IPO
ListedMainboardOpens 14 July 2025Closes 16 July 2025
Anthem Biosciences is a technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) for drug discovery, development and manufacturing. It offers comprehensive CRDMO services across the New…
Anthem Biosciences is a technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) for drug discovery, development and manufacturing. It offers comprehensive CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company also manufactures and sells Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. As of March 31, 2024, the company had 550 customers in over 44 countries.
Show moreShow less
Key ratios
As per RHP / filingsTimeline
IPO Opens
14 Jul
IPO Closes
16 Jul
Allotment
17 Jul
Listing
21 Jul
IPO Timeline & Listing Details
| Event | Date |
|---|---|
| IPO Open Date | 14 July 2025 |
| IPO Close Date | 16 July 2025 |
| Allotment Date | 17 July 2025 |
| Listing Date | 21 July 2025 |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,820 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,92,660 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,07,480 |
SHNI (Max)Below ₹10,00,000 | 67 | ₹9,92,940 |
BHNIAbove ₹10,00,000 | 68 | ₹10,07,760 |
IPO Objectives
- The Company will not receive any proceeds from the Offer as it is a 100% Offer for Sale. All proceeds will go to the selling shareholders after deductions for offer-related expenses and taxes.
Strengths
- Fastest-growing CRDMO with broad service offerings for small molecules and biologics.
- Innovation-focused with advanced technological solutions across various drug development areas.
- Differentiated business model catering to small pharmaceutical and emerging biotech companies.
- Long-standing relationships with a large and diverse customer base.
- Wide specialty ingredients portfolio, well-positioned for market opportunities.
- Automated manufacturing infrastructure with a strong regulatory compliance record.
Weaknesses
- The entire IPO is an Offer for Sale, meaning the company will not receive any proceeds.
- High revenue concentration: Top 5 customers contributed ~71% of revenue in FY25, and over 55% of revenue comes from Europe.
- Manufacturing facilities are concentrated in Karnataka, posing regional risks.
- Vulnerable to rapid technological changes and evolving industry standards, requiring continuous investment.
Financial Performance
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹ Cr.) | 2,807.58 | 2,398.11 | 2,014.46 |
| Revenue (₹ Cr.) | 1,930.29 | 1,483.07 | 1,133.99 |
| PAT (₹ Cr.) | 451.26 | 367.31 | 385.19 |
| Net Worth (₹ Cr.) | 2,409.86 | 1,924.66 | 1,740.67 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Anthem Biosciences Limited | 13.23 | 70.62 | 20.82% | 2,409.86 |
| Syngene International Ltd | 5.46 | 52.08 | 10.5% | 4,727 |
| Sai Life Sciences Limited | 8.07 | 100.98 | 7.99% | 975 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0.39x | 0.62x | 192.8x |
| NII | 1.64x | 10.26x | 44.69x |
| S-HNI | 2.02x | 9.93x | 30.76x |
| B-HNI | 1.44x | 10.42x | 51.66x |
| RII | 0.62x | 2.21x | 5.92x |
| EMP | 1.04x | 2.74x | 6.89x |
| Total | 0.77x | 3.48x | 67.39x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 1,18,83,334 | 2,29,10,95,976 | 1,30,592.47 |
| NII | 89,12,500 | 39,83,06,792 | 22,703.49 |
| Small NII | 29,70,833 | 9,13,88,258 | 5,209.13 |
| Big NII | 59,41,667 | 30,69,18,534 | 17,494.36 |
| RII | 2,07,95,833 | 12,32,07,422 | 7,022.82 |
| EMP | 1,58,654 | 10,93,274 | 62.32 |
| Total | 4,17,50,321 | 2,81,37,03,464 | 1,60,381.1 |
Company Details
- Anthem Biosciences Ltd.
- No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka-560099, India
- +91 080 6672 400
- investors.abl@anthembio.com
- https://www.anthembio.com/
Registrar Details
- Kfin Technologies Limited
- 04067162222, 04079611000
- anthem.ipo@kfintech.com
- https://kosmic.kfintech.com/ipostatus/
Frequently Asked Questions
See live numbers on GMP, Subscription, and Allotment pages.
Anthem Biosciences IPO News & Updates
Follow the latest updates for Anthem Biosciences IPO, including grey market moves and allotment news.
Anthem Biosciences IPO IPO Pages
Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.
Anthem Biosciences IPO Details
Issue size, price, financials, and company info
Anthem Biosciences IPO GMP
Live grey market premium and listing estimate
Anthem Biosciences IPO Subscription
QIB, NII, Retail, SHNI and BHNI subscription
Anthem Biosciences IPO Allotment
Allotment date, chances, and check by PAN
Anthem Biosciences IPO Review
SWOT, strengths, risks, and IPO review
Anthem Biosciences IPO FAQ
Common questions on dates, GMP, and allotment
Anthem Biosciences IPO Registrar
Registrar website and how to check allotment
Anthem Biosciences IPO Timeline
Open, close, allotment, and listing dates
Anthem Biosciences IPO News
Updates, blogs, and latest IPO news
Sources
We match Anthem Biosciences IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.
- SEBIRules for IPO allotment and disclosures in India
- NSEExchange notices, bidding data, and listing updates
- BSEExchange notices and IPO allotment check tools
- RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
- Kfin Technologies LimitedOfficial site to check allotment status for this IPO
Also read our Editorial Policy, How GMP is calculated, How allotment chances work, and IPO fund allocation.
Reviewed by
Dinesh Agrawal · Lead IPO Analyst
15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.